Ayala Pharmaceuticals, Inc.

OTCPK:ADXS Stock Report

Market Cap: US$1.8m

Ayala Pharmaceuticals Management

Management criteria checks 1/4

Ayala Pharmaceuticals' CEO is Ken Berlin, appointed in Oct 2023, has a tenure of 1.58 years. total yearly compensation is $736.29K, comprised of 94.2% salary and 5.8% bonuses, including company stock and options. directly owns 0.001% of the company’s shares, worth $10.17. The average tenure of the management team and the board of directors is 1.6 years and 1.6 years respectively.

Key information

Ken Berlin

Chief executive officer

US$736.3k

Total compensation

CEO salary percentage94.18%
CEO tenure1.6yrs
CEO ownership0.0006%
Management average tenure1.6yrs
Board average tenure1.6yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Ken Berlin's remuneration changed compared to Ayala Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$736kUS$693k

-US$48m

Compensation vs Market: Ken's total compensation ($USD736.29K) is about average for companies of similar size in the US market ($USD647.92K).

Compensation vs Earnings: Insufficient data to compare Ken's compensation with company performance.


CEO

Ken Berlin (60 yo)

1.6yrs
Tenure
US$736,290
Compensation

Mr. Kenneth A. Berlin, also known as Ken, J.D., serves as President, Chief Executive Officer & Director at Ayala Pharmaceuticals, Inc. (Formerly known as Advaxis, Inc.) since October 19, 2023. He served as...


Leadership Team

NamePositionTenureCompensationOwnership
Kenneth Berlin
CEO, President & Director1.6yrsUS$736.29k0.00055%
$ 10.2
Irit Klipper-Avni
Vice President of Human Resources1.6yrsno datano data
Dana Gelbaum
GM & Chief Business Officer1.6yrsno datano data
1.6yrs
Average Tenure

Experienced Management: ADXS's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Kenneth Berlin
CEO, President & Director1.6yrsUS$736.29k0.00055%
$ 10.2
Roni Appel
Independent Director1.6yrsno data0.00027%
$ 5.0
Murray Goldberg
Independent Director1.6yrsno data0%
$ 0
David Sidransky
Chairman1.6yrsno data0.00019%
$ 3.5
Robert Jay Spiegel
Independent Director1.6yrsno data0%
$ 0
Pini Orbach
Director1.6yrsno datano data
Vered Bisker-Leib
Independent Vice Chairman1.6yrsno data0%
$ 0
Yuval Cabilly
Director1.6yrsno datano data
1.6yrs
Average Tenure
59.5yo
Average Age

Experienced Board: ADXS's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/21 09:28
End of Day Share Price 2025/05/19 00:00
Earnings2023/12/31
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Ayala Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ahu DemirLadenburg Thalmann & Company